The disappointing results seen with modulation of NF-kB do not exclude this pathway as a potential therapeutic target, as the events leading to NF-kB upregulation in DLBCL are heterogeneous. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.